- Supported exchanges /
- F /
- 6JH.F
IN8BIO INC. DL-0001 (6JH F) stock market data APIs
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
IN8BIO INC. DL-0001 Financial Data Overview
| 0.242 | |
| 0.25 | |
| - | |
| 0.25 | |
| 0.242 | |
| 0.202-1.74 | |
| 18 266 K | |
| 72 546 K | |
| 0 | |
| -0.249 | |
| -0.051 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
IN8BIO INC. DL-0001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -30 632 000
- Earnings Per Share -0.76
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get IN8BIO INC. DL-0001 Earnings via APIs
- Latest Release 2023-06-30
- EPS/Forecast NaN
Get IN8BIO INC. DL-0001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
